COVAX Data Show Similar COVID-19 Vaccine Safety Between General Public, Patients With RMD
The safety profiles of COVID-19 vaccines in patients with inflammatory rheumatic and musculoskeletal disease (RMD) was comparable with patients with non-inflammatory RMD and the general population, according to a new study.
New COVAX data revealed the safety profiles of COVID-19 vaccines in patients with inflammatory
“These are valuable findings which will support discussions about the safety and benefit/risk ratio of COVID vaccination for people with RMDs,”
Rheumatologists were asked to report as many cases as possible of patients who had received a COVID vaccine and whether they had experienced side effects.
Data from 5121 people in 30 countries with RMD who received at least 1 dose of a COVID-19 vaccine was collected between February and July 2021.
The majority of patients (70%) were female. The mean (SD) age was 61.6 years (15.2) with 56% of cases being over age 60. The I-RMD group made up 90% of cases and the NI-RMD group made up the other 10%.
The most common I-RMDs were rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis, and the most common NI-RMDs were osteoarthritis and osteoporosis.
According to the study published in
“Interestingly, in clinical trials of mRNA, inactivated and non-replicating vector vaccines against SARS-CoV-2 in the general population, the pooled rates of SAEs were very similar to our study, ranging from 0.4% to 0.6% in the vaccine group, and from 0.5% to 0.6% in the control group, suggesting that these SAEs are not necessarily causally related to the vaccine and might be coincidental observations,” the study authors noted.
Among those with I-RMDs, 54% were taking a conventional synthetic disease-modifying antirheumatic drug, 42% were on biological DMARDs, and 35% were taking immunosuppressant medicines for their RMD (glucocorticoids, mycophenolate, azathioprine). More than 98% of people included in the study were able to continue their normal medication with no changes.
The majority received the Pfizer/BioNTech vaccine (70%), followed by AstraZeneca/Oxford (17%) and then Moderna (8%). Only 1% of participants had 3 doses during the time frame, 74% had 2 doses, and 25% had 1 dose. The most common side effects were short-lived reactions to the vaccine injection and, once they were fully vaccinated, there was a low rate of COVID-19 infections in people with RMD (I-RMD, 0.7%; NI-RMD, 1.1%).
“These findings should provide reassurance to rheumatologists and vaccine recipients and promote confidence in SARS-CoV-2 vaccine safety in I-RMD patients,” the authors said.
Reference
Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. Published online December 31, 2021. doi:10.1136/annrheumdis-2021-221490
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025